Structure

InChI Key PYTMYKVIJXPNBD-UHFFFAOYSA-N
Smile CCN(CC)CCOc1ccc(C(=C(Cl)c2ccccc2)c2ccccc2)cc1.O=C(O)CC(O)(CC(=O)O)C(=O)O
InChI
InChI=1S/C26H28ClNO.C6H8O7/c1-3-28(4-2)19-20-29-24-17-15-22(16-18-24)25(21-11-7-5-8-12-21)26(27)23-13-9-6-10-14-23;7-3(8)1-6(13,5(11)12)2-4(9)10/h5-18H,3-4,19-20H2,1-2H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)

Physicochemical Descriptors

Property Name Value
Molecular Formula C32H36ClNO8
Molecular Weight 598.09
AlogP 6.56
Hydrogen Bond Acceptor 2.0
Hydrogen Bond Donor 0.0
Number of Rotational Bond 9.0
Polar Surface Area 12.47
Molecular species BASE
Aromatic Rings 3.0
Heavy Atoms 29.0

Pharmacology

Action Mechanism of Action Reference
MODULATOR Estrogen receptor alpha modulator Wikipedia FDA

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Polycystic Ovary Syndrome 4 D011085 ClinicalTrials
Infertility, Female 1 D007247 ClinicalTrials

Related Entries

Scaffolds

Parent

Adverse Reactions

System Organ Classification (SOC)
Relative Frequency (%)
Pregnancy, puerperium and perinatal conditions
15.07
Injury, poisoning and procedural complications
8.45
Psychiatric disorders
7.94
Nervous system disorders
7.5
General disorders and administration site conditions
6.62
Reproductive system and breast disorders
6.49
Vascular disorders
5.74
Gastrointestinal disorders
5.17
Cardiac disorders
4.1
Investigations
3.78
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
3.53
Eye disorders
3.47
Congenital, familial and genetic disorders
3.4
Musculoskeletal and connective tissue disorders
2.59
Skin and subcutaneous tissue disorders
2.46
Respiratory, thoracic and mediastinal disorders
2.33
Endocrine disorders
2.14
Metabolism and nutrition disorders
2.02

Cross References

Resources Reference
ChEBI 3753
ChEMBL CHEMBL3185958
EPA CompTox DTXSID8020337
FDA SRS 1B8447E7YI
ZINC ZINC01530601